Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-controlled, Single-Center Study to Evaluate the Safety and Efficacy of Stemchymal (Allogeneic Adipose-derived Mesenchymal Stem Cells) Infusion for the Treatment of PolyQ Spinocerebellar Ataxia
NCT06397274 is registered in ClinicalTrials.gov with Steminent US, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized, Double-Blind, Placebo-controlled, Single-Center Study to Evaluate the Safety and Efficacy of Stemchymal (Allogeneic Adipose-derived Mesenchymal Stem Cells) Infusion for the Treatment of PolyQ Spinocerebellar Ataxia
- Lead sponsor
- Steminent US, Inc.
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- June 1, 2025
- Completion date
- June 1, 2028
- Enrollment
- 20 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.